Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke

Stroke

Volumn 43, Issue 9, 2012, Pages 2300-2306

  Donohue, Megan M ^a   Cain, Kevin ^a   Zierath, Dannielle ^a   Shibata, Dean ^a   Tanzi, Patricia M ^a   Becker, Kyra J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CX3CL1; fractalkine; inflammation; outcome; stroke

Indexed keywords

C REACTIVE PROTEIN; FRACTALKINE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD LEVEL; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBRAL INFARCTION; CHEMOKINE CX3CL1; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTE COUNT; MALE; MIDDLE AGED; STROKE; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84865583063     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.657411     Document Type: Article

References (42)

1. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-644.
2. Fong S, Jones S, Renz ME, Chiu HH, Ryan AM, Presta LG, et al. Mucosal addressin cell adhesion molecule-1 (MADCAM-1). ITS binding motif for alpha 4 beta 7 and role in experimental colitis. Immunol Res. 1997;16:299-311.
3. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-530.
4. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998;95:10896-10901.
5. Ruitenberg MJ, Vukovic J, Blomster L, Hall JM, Jung S, Filgueira L, et al. CX3CL1/fractalkine regulates branching and migration of monocyte-derived cells in the mouse olfactory epithelium. J Neuroimmunol. 2008; 205:80-85.
6. Krathwohl MD, Kaiser JL. Chemokines promote quiescence and survival of human neural progenitor cells. Stem Cells. 2004;22:109-118.
7. Maggi L, Scianni M, Branchi I, D'Andrea I, Lauro C, Limatola C. CX(3)CR1 deficiency alters hippocampal-dependent plasticity phenomena blunting the effects of enriched environment. Front Cell Neurosci. 2011;5:22.
8. Bachstetter AD, Morganti JM, Jernberg J, Schlunk A, Mitchell SH, Brewster KW, et al. Fractalkine and CX3CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol Aging. 2011;32: 2030-2044.
9. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol. 2010;177:2549-2562.
10. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem. 2011;286:32713-32722.
11. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation. 2011;8:9.
12. Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T, et al. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiol Aging. 2011;32:443-458.
13. Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci. 2002;15: 1663-1668.
14. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, et al. Mice deficient in fractalkine are less susceptible to cerebral ische-mia-reperfusion injury. J Neuroimmunol. 2002;125:59-65.
15. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008;28: 1707-1721.
16. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol. 2003;137: 210-217.
17. Rancan M, Bye N, Otto VI, Trentz O, Kossmann T, Frentzel S, et al. The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury. J Cereb Blood Flow Metab. 2004;24:1110-1118.
18. Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythema-tosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670-1675.
19. Kasama T, Odai T, Wakabayashi K, Yajima N, Miwa Y. Chemokines in systemic lupus erythematosus involving the central nervous system. Front Biosci. 2008;13:2527-2536.
20. Fassbender K, Mossner R, Motsch L, Kischka U, Grau A, Hennerici M. Circulating selectin-and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke. 1995;26:1361-1364.
21. Blann A, Kumar P, Krupinski J, McCollum C, Beevers DG, Lip GY. Soluble intercellular adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand Factor in stroke. Blood Coagul Fibrinolysis. 1999;10:277-284.
22. Shyu KG, Chang H, Lin CC. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. J Neurol. 1997;244:90-93.
23. Simundic AM, Basic V, Topic E, Demarin V, Vrkic N, Kunovic B, et al. Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med. 2004;27:86-92.
24. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA stroke trial investigators. Stroke. 1999;30: 2347-2354.
25. van Swieten J, Koudstaal P, Visser M, Schouten H, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
26. Levin HS, Boake C, Song J, McCauley S, Contant C, Diaz-Marchan P, et al. Validity and sensitivity to change of the extended Glasgow Outcome Scale in mild to moderate traumatic brain injury. J Neurotrauma. 2001; 18:575-584.
27. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES, Lev MH, et al. ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology. 2009;72:2104-2110.
28. Zierath D, Tanzi P, Cain K, Shibata D, Becker K. Plasma {alpha}-melanocyte stimulating hormone predicts outcome in ischemic stroke. Stroke. 2011;42:3415-3420.
29. Tanzi P, Cain K, Kalil A, Zierath D, Savos A, Gee JM, et al. Post-stroke infection: a role for IL-1ra? Neurocrit Care. 2011;14:244-252.
30. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU. Fractalkine and frac-talkine receptors in human neurons and glial cells. J Neurosci Res. 2002;69:418-426.
31. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci. 2000;20:RC87.
32. Zujovic V, Benavides J, Vige X, Carter C, Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia. 2000;29:305-315.
33. Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003;979:65-70.
34. Duan RS, Yang X, Chen ZG, Lu MO, Morris C, Winblad B, et al. Decreased fractalkine and increased IP-10 expression in aged brain of APP(SWE) transgenic mice. Neurochem Res. 2008;33:1085-1089.
35. Lyons A, Lynch AM, Downer EJ, Hanley R, O'Sullivan JB, Smith A, et al. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attenuates microglial activation in vivo and in vitro. J Neu-rochem. 2009;110:1547-1556.
36. Corona AW, Huang Y, O'Connor JC, Dantzer R, Kelley KW, Popovich PG, et al. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J Neuroinflammation. 2010;7:93.
37. Lauro C, Cipriani R, Catalano M, Trettel F, Chece G, Brusadin V, et al. Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against GLU-induced death. Neuropsychopharmacology. 2010;35:1550-1559.
38. Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, et al. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci. 2011;31:16327-16335.
39. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A. 2000;97:8075-8080.
40. Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, Di Angelantonio S, et al. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol. 2005;166: 19-28.
41. Deiva K, Geeraerts T, Salim H, Leclerc P, Hery C, Hugel B, et al. Fractalkine reduces N-methyl-D-aspartate-induced calcium flux and apo-ptosis in human neurons through extracellular signal-regulated kinase activation. Eur J Neurosci. 2004;20:3222-3232.
42. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, et al. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2008;436:196-200.